Axogen forecasts at least $290M 2026 revenue, adds $7M from BioCircuit while planning prostate market development in 2027 (NASDAQ:AXGN)

seekingalpha.com · 2026-10-28

Axogen Q3 2026 earnings: revenue jumped 26%, guidance rose to $290M, and BioCircuit adds NerveTape growth potential.